Breaking through the barrier

In many advanced cancers, tumour cells are protected by a dense and complex microenvironment, including cancer‑associated fibroblast or CAFs.

This barrier limits drug delivery, suppresses immune response and enables disease progression — reducing the effectiveness of both targeted therapies and immunotherapies.

Theolytics is developing systemically deliverable immunotherapies based on oncolytic adenoviruses designed to break through the barriers of solid tumours.

Using our Adenovo™ platform, we identify viral candidates capable of selectively targeting and destroying both cancer cells and the surrounding tumour‑supporting stroma- enabling a more complete and clinically meaningful therapeutic response.